Press Releases
Latest insights, analysis, and updates from our experts.
Precision Medicine Diagnostics Solutions Market is expected to reach USD 122.6 billion by 2031
According to government health organisations, precision diagnostics play a key role in making clinical decisions. For example, genomic sequencing and biomarker-based tests can help determine which therapies are chosen. The National Cancer Institute states that national laboratory networks now utilize standardized next-generation sequencing (NGS) assays to match patients with targeted therapies during clinical trials such as MATCH and ComboMATCH, increasing the accuracy of treatment distribution. Additionally, recent government-funded studies, notably California’s precision medicine initiative, have enrolled more than 220,000 individuals in research studies involving genomics and screening, thus increasing the volume of real-life diagnostic data. These regulatory and research developments indicate that diagnostics are transitioning to multi-biomarker, data-driven platforms integrated into the clinical workflow.
Pharmacogenomics Testing Market is anticipated to surpass US$17.9 billion in 2031 at a CAGR of 10.0%
The pharmacogenomics testing market is expanding as precision medicine gains momentum worldwide. Advancements in NGS and PCR technologies, rising oncology applications, and increasing awareness of personalized treatments are driving demand. North America leads the market, while Asia Pacific shows rapid growth. Key companies are enhancing genomic testing capabilities through innovation and partnerships.
Point-of-Care Diagnostic Devices Market is expected to reach USD 88.8 billion by 2031
The point-of-care diagnostic devices market is growing as more people desire rapid, on-location testing and expedited clinical decisions. Growing applications in chronic and infectious disease detection, coupled with revolutionary portable technologies, are major factors behind the market growth. However, issues related to accuracy and regulations pose challenges.
Predictive Analytics For Disease Diagnostics Market is expected to reach USD 12.5 billion by 2031
The market for predictive analytics for disease diagnostics is growing fast because the healthcare industry is moving towards the use of AI and data-based insights for early detection and preventive care. These technologies, which analyze clinical, genomic, and patient data, help in early identification of diseases and in making better treatment decisions. Large companies such as IBM, Oracle Health, SAS Institute, and Siemens Healthineers are leading these technologies.
Molecular Diagnostics Technologies Market is anticipated to surpass US$33.5 billion in 2031 at a CAGR of 8.9%
The molecular diagnostics market is growing due to rising demand for early detection, precision medicine, and infectious disease testing. Advanced technologies like PCR and NGS enhance accuracy and speed. North America leads, while Asia Pacific expands rapidly. Reagents and kits dominate, with strong competition driven by innovation, partnerships, and increasing global healthcare investments.
Multi-Omics Diagnostics Integration Platforms Market is expected to reach USD 9.1 billion by 2031
The global market for multi-omics diagnostics integration platforms is robustly growing due to the ever-growing complexity of diseases and the demand for integrated, data-driven diagnostic platforms. Multi-omics approaches allow the integration of various biological data such as genomics, proteomics, transcriptomics, metabolomics and epigenomics to gain a comprehensive understanding of disease processes. They are used for detection, diagnosis and personalised therapies. Coupled with cutting-edge bioinformatics and data analytics techniques, multi-omics technologies can be used in cancer research, rare genetic diseases, neurology, immunology and precision medicine.
Next-Generation Sequencing (NGS) Diagnostics Market is expected to reach USD 44.8 billion by 2031
The next-generation sequencing (NGS) diagnostics market is developing strongly around the world, as the number of cancer cases is on the rise, and the need for high-throughput, precise, and real-time diagnostics is increasing. NGS technologies can be used to provide overall genomic profiling to detect disease at an early stage, accurately diagnose it, and create individual treatment plans. Combining NGS with sophisticated bioinformatics software further improves its use in the clinical field of oncology, infectious diseases, and the diagnosis of genetic disorders.
Epigenetics Diagnostics Market is expected to reach USD 44.7 billion by 2031
The epigenetics diagnostics market is growing at a steady pace as the need for identifying diseases quickly and accurately, especially cancers and neurological disorders, has increased. Next-generation sequencing and PCR, for instance, are able to pinpoint the epigenetic changes, such as DNA methylation, with a high level of accuracy, thereby facilitating personalized medicine and non-invasive diagnostics in the form of liquid biopsies. More research funds, along with technological innovations and the incorporation of AI-based data analysis, are the major factors supporting the growth of the market. However, expensive testing and a lack of standardization in test methods are the main issues of concern.
Liquid Biopsy Diagnostics Market is expected to reach USD 14.4 billion by 2031
The global liquid biopsy diagnostics market is growing at a rapid pace. This can largely be attributed to the rising number of cancer patients and the increased preference for non-invasive and real-time diagnostic solutions. Liquid biopsy is a promising approach that allows early detection, treatment co-monitoring, and personalization of therapies using biomarkers derived from different body fluids. This method is further enabled by technology innovations such as NGS and digital PCR. Even though high costs and lack of standardization pose barriers, continuous research and product development, along with the discovery of new clinical applications, are likely to significantly contribute to the expansion of the market.
Digital Pathology and AI Assisted Microscopy Market is anticipated to surpass US$3.7 billion in 2031 at a CAGR of 18.3%
AI-driven digital pathology is transforming diagnostics by improving accuracy, speed, and scalability amid rising sample volumes and workforce shortages. Growing adoption is fueled by healthcare digitalization and regulatory support. North America leads the market, while Asia Pacific shows strong growth potential, with cancer diagnostics and AI-powered imaging technologies driving demand across healthcare systems globally.
Clinical Decision Support Diagnostic Systems Market is anticipated to surpass US$4.3 billion in 2031 at a CAGR of 9.8%
Regulatory reforms and government-backed digital health initiatives are transforming clinical decision support systems. AI-based SaMD solutions with interoperability, explainability, and compliance are driving adoption. Integrated CDSS and diagnostic support lead growth, while North America dominates and Asia Pacific rapidly expands, supported by digital infrastructure, regulatory frameworks, and increasing deployment of machine learning models.
Machine Learning–Based Diagnostic Imaging Platforms Market is anticipated to surpass US$5.1 billion in 2031 at a CAGR of 19.4%
Machine learning enhances radiology workflows by improving diagnostic accuracy and enabling faster results. Imaging demand, radiologist shortages, and regulatory approvals drive global adoption. Cloud-based and tele-radiology solutions support remote diagnostics. Oncology leads applications, while CT and MRI dominate modalities. North America leads, Asia Pacific grows due to expanding healthcare infrastructure.